Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01850654 · ClinicalTrials.gov registry record · NA
Ohio Colorectal Cancer Prevention Initiative
A NA study, sponsored by Ohio State University Comprehensive Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 3,470
- Enrollment target
NCT01850654: Completed NA study, sponsored by Ohio State University Comprehensive Cancer Center.
NCT01850654 is a NA study that has completed, run by Ohio State University Comprehensive Cancer Center. The registered enrollment target is 3,470 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (147% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01850654, a NA study, has completed, sponsored by Ohio State University Comprehensive Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 3,470 participants
- Enrollment target
Study Summary
The purpose of the Ohio Colorectal Cancer Prevention Initiative (OCCPI) is to reduce morbidity and mortality due to colorectal cancer (CRC) in the state of Ohio. By identifying individuals at high-risk for CRC (genetically predisposed) and providing screening recommendations for cancer risk reduction, the OCCPI will understand how to increase length of life and quality of life for those diagnosed with CRC in Ohio, as well as to better prevent CRC in others in Ohio. Participants will have free tumor screening for Lynch syndrome, and may be eligible for free genetic testing and free genetic counseling as part of this study.
Primary Outcome
Through tumor testing for Lynch syndrome and follow-up genetic testing for all patients with abnormal tumor testing and select patients with normal tumor testing (those diagnosed under age 50 and those at or over age 50 with a first degree relative with colorectal or endometrial cancer or synchronous or metachronous colon or endometrial cancer).
Interventions
- BEHAVIORAL Questionnaire
- GENETIC Genetic testing
- OTHER Biorepository
- BEHAVIORAL Genetic Counseling
- GENETIC LS tumor screening
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,470 participants |
| Start Date | 2012-12-26 |
| Est. Completion | 2018-01-02 |
| Phase | NA |
What the finished NCT01850654 record still lists
NCT01850654 is an interventional study that assigns participants to a tested intervention. Its 3,470 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (147% higher).
The record links to 0 conditions, and to 5 interventions - of which Questionnaire is the first listed.
NCT01850654 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01850654 about?
NCT01850654 is a clinical study titled "Ohio Colorectal Cancer Prevention Initiative". The purpose of the Ohio Colorectal Cancer Prevention Initiative (OCCPI) is to reduce morbidity and mortality due to colorectal cancer (CRC) in the state of Ohio. By identifying individuals at high-risk for CRC (genetically predisposed) and providing screening recommendations for cancer risk reductio...
What is the current status of trial NCT01850654?
This trial is currently completed. It is a NA study. The enrollment target is 3,470 participants. The study started on 2012-12-26. Estimated completion is 2018-01-02.
What interventions are being tested in trial NCT01850654?
The interventions under investigation include: Questionnaire (BEHAVIORAL), Genetic testing (GENETIC), Biorepository (OTHER), Genetic Counseling (BEHAVIORAL), LS tumor screening (GENETIC).
Who is sponsoring clinical trial NCT01850654?
This trial is sponsored by Ohio State University Comprehensive Cancer Center, which has 341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01850654's enrollment target sits among peer trials
3,470 37th of 2000 higher than 1,964 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00260559 · 3,500 participants
Outcomes After Esophagectomy With a Focus on Minimally Invasive Esophagectomy and Quality of Life
- NCT01612949 · 3,500 participants
Facial Analysis to Classify Difficult Intubation
- NCT02398786 · 3,500 participants
Myotonic Dystrophy Family Registry
- NCT03486873 · 3,500 participants · Phase 3
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI